Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical trial at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’
Researchers still think patients should receive an injectable version of semaglutide when possible, but new data out of ACC.25 confirm that an oral formulation of the drug is associated with significant benefits.
‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.
FDA chooses not to approve new nasal spray for heart rhythm issues
Etripamil's journey toward FDA approval hit a roadblock. The agency requested additional information on the drug, including a new facility inspection, in a response letter sent to Milestone Pharmaceuticals.

Vericiguat consistently linked to positive outcomes, limited side effects among heart failure patients

Reviewing data from several studies, researchers wrote that vericiguat (Verquvo) could potentially "become a breakthrough in the treatment of heart failure."

FDA calls out weight loss pills for ‘hidden’ ingredient that puts health of heart patients at risk

The agency’s own analysis confirmed that these capsules contain sibutramine, which was removed from the market back in 2010 due to safety concerns

CardiacSense, an Israel-based healthcare technology company, gained FDA clearance for its CSF-3 medical watch

Regulatory Roundup: FDA clears new medical watch, considers empagliflozin for CKD and much more

Our monthly review of FDA-related news items in the world of cardiology includes updates from CardiacSense, MedAlliance, Lupin, Realize Medical and Eli Lilly and Company.

FDA approves new medication for type 2 diabetes

The newly approved SGLT2 inhibitor, bexagliflozin, is marketed under the name Brenzavvy. It is not recommended for patients with type 1 diabetes.

Peter Libby, MD, a cardiovascular medicine specialist, Brigham and Women’s Hospital, and Mallinckrodt Professor of Medicine, Harvard Medical School, explains the take aways from the PROMINENT trial using pemafibrate to lower cardiovascular risks. The trial, presented at the American Heart Association (AHA) 2022 meeting, did not show reduction in the incidence of cardiovascular events among those who received pemafibrate than among those who received placebo. #AHA #AHA22

VIDEO: Pemafibrate does not lower cardiovascular risks in the PROMINENT trial

Peter Libby, MD, a cardiovascular medicine specialist with Brigham and Women’s Hospital and Harvard Medical School, explained some key takeaways from the PROMINENT trial.

How cardiologists can improve in-hospital outcomes after PCI

Researchers evaluated if two recently developed risk scores can anticipate adverse in-hospital outcomes after PCI, sharing their findings in the American Journal of Cardiology.

A new antiplatelet strategy for treating diabetic PCI patients

Clopidogrel monotherapy after just one month of DAPT was associated with promising outcomes, including a reduction in bleeding events.

VIDEO: Why does COVID-19 damage vascular beds?

Peter Libby, MD, a cardiovascular medicine specialist at Brigham and Women’s Hospital, explains his research into COVID-19 and how it damages the endothelium of blood vessels.

Pharmaceutics

Key takeaways from ACC.25: Advances in cardiovascular science

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Oral semaglutide reduces heart risks while helping patients move past ‘fear of the needle’

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes

FDA chooses not to approve new nasal spray for heart rhythm issues